Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Transplantation of hepatitis C virus (HCV) nucleic acid (NAT) positive organs is associated with shorter time to transplant and decreased risk of death on the waiting list. Treatment for HCV post-transplant is well-tolerated, successful, and leads to similar transplant outcomes to patients transplanted with HCV NAT- organs. Despite these outcomes, not all patients consent to receive HCV NAT+ organs, and factors associated with consent are not well-known.
Methods: This retrospective single-center study of adult patients listed for heart, liver, lung, and kidney transplant aimed to determine whether sociodemographic and organ-specific disparities exist in consent for HCV NAT+ donor organs.
Results: Of 2788 transplant candidates, 44% (N = 1229) consented to receive an HCV NAT+ organ. Patients who designated English as their preferred language were more likely to consent compared to a non-English preference (45% vs. 19%, p < 0.001). Consent rates were highest amongst patients listed for liver transplantation compared to kidney, heart, and lung transplants (67%, N = 319 vs. 42%, N = 602 vs. 38%, N = 159 vs. 32%, N = 149; p < 0.001).
Conclusions: Overall, more efforts are needed to ensure that all patients who may benefit from consenting for HCV NAT+ organs are appropriately educated in their language of choice on the risks and benefits.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ctr.70186 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hepatitis C virus NS3 helicase contributes to (-) strand RNA synthesis.
Nat Commun
August 2025
Department Infectious Diseases, Molecular Virology, Heidelberg University, Medical Faculty, Heidelberg, Germany.
Many positive strand RNA viruses encode helicases, but their distinct functions in viral replication cycles is poorly understood. Here, we identify a mutation in the helicase domain of HCV non-structural protein 3 (NS3h), D1467G, which specifically affects (-) strand synthesis, phenocopying mutations in the 3' untranslated region of the genome. D1467G does not impair helicase activity in vitro or the binding of NS3h to critical cis-acting RNA elements, but reduces the interaction of NS3h and NS5B polymerase, potentially contributing to defective (-) strand synthesis.
View Article and Find Full Text PDFDesign and nonviral delivery of live attenuated vaccine to prevent chronic hepatitis C virus-like infection.
Nat Commun
August 2025
Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
An effective vaccine for the hepatitis C virus (HCV) remains an unmet medical need. There is no animal model for assessing HCV vaccines; however, rodent hepacivirus (RHV) infection in laboratory rats recapitulates the lifelong chronic hepatotropic infection and immune evasion of HCV. Here, we designed a live-attenuated vaccine (LAV) for RHV and determined its immunogenicity and efficacy for preventing chronic infection.
View Article and Find Full Text PDFHigh false hepatitis C antibody positivity rate in a regionally-inclusive population of non-renumerated blood donors in Uganda.
Afr Health Sci
September 2024
School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Background: Successful elimination of hepatitis as a public health threat by 2030 will partly rely on the availability and accessibility of affordable accurate disease testing platforms. In the past, testing of hepatitis C virus (HCV) in low resource settings of sub-Saharan Africa (SSA) has relied on anti-HCV testing using rapid diagnostic tests, chemiluminescent microparticle immunoassay (CMIA) and Enzyme-linked Immunosorbent Assays (ELISA) whose diagnostic accuracy has been sub-optimal. We determined the false positivity rate of a CMIA platform that is routinely used to screen donor blood for anti-HCV in Uganda.
View Article and Find Full Text PDFStructural insights into polymerase-catalyzed FAD capping of hepatitis C virus RNA.
Nat Commun
August 2025
Beijing Frontier Research Center for Biological Structure, Center for Infectious Disease Research, SXMU-Tsinghua Collaborative Innovation Center for Frontier Medicine, Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China.
The RNA polymerase NS5B of HCV is capable of catalyzing the addition of flavin adenine dinucleotide (FAD) to its RNA as a 5' cap structure, aiding the virus in evading host immune responses. However, the exact mechanism underlying the 5'-FAD capping process of HCV RNA remains to be elucidated. Here, we determine crystal structures of the HCV NS5B de novo initiation, primed initiation and elongation complexes in presence of FAD.
View Article and Find Full Text PDFNucleic acid testing in Colombian blood banks (2018-2024): Implementation, yield estimates and implications for safer transfusion policy.
Vox Sang
August 2025
School of Medicine and Health Science, Public Health Research Group, Universidad del Rosario, Bogotá, Colombia.
Background And Objectives: Colombia has a population of 52.6 million inhabitants and a blood donation rate of 26 donations per 1000 inhabitants. The 84 blood banks in the country collect approximately 1 million donations annually, which are mandatorily screened for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), human T-lymphotropic virus (HTLV), Trypanosoma cruzi and Treponema pallidum.
View Article and Find Full Text PDF